How the product works:
Ropinirole is a selective dopamine D2/D3 receptor agonist. It compensates for dopamine deficiency in the central nervous system, reducing tremor, rigidity, and bradykinesia. The extended-release formulation provides stable plasma levels over 24 hours.
Who it is recommended for:
Clinical studies and evidence:
Clinical trials have demonstrated that extended-release ropinirole improves motor control and reduces nocturnal symptoms. The drug is included in international treatment guidelines for Parkinson’s disease and restless legs syndrome.
The medication acts by stimulating dopamine receptors, improving motor and sensory symptoms.
The drug is taken orally once daily at the same time each day, with or without food. Tablets should be swallowed whole and not crushed or chewed. Dosage and treatment duration are determined by a healthcare professional.
Contraindications:
Side effects:
